Autobio Diagnostics Co (603658) Fair Value & Analysis
Healthcare · CN · Market cap 18.3B CNY
Fair value as of: Jul 11, 2026
From 26 valuation models · updated 30 days ago
Fair value updated Jul 11, 2026, revised from ¥40.03 to ¥34.71 (−13.3%) since Jun 24, 2026. Share price +5.1% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥25.68 (bear) to ¥43.30 (bull), base ¥34.71. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 67/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
60‑month range ¥28.72 – ¥98.68 · fair‑value band ¥25.68 – ¥43.30 · the ¥32.43 price screens below the ¥34.71 fair value. Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Autobio Diagnostics Co (603658) currently trades at ¥32.43, while our model-based Fair Value estimate is ¥34.71, implying the stock looks roughly 7.0% fairly valued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Autobio Diagnostics Co generated revenue of 4.2B CNY at a net margin of 24.5%. Revenue declined 0.4% year over year. It earns a return on equity of 11.6%. The balance sheet holds a net cash position of 212M CNY. Fundamentals as of Jul 11, 2026
Our scenario range runs from ¥25.68 (bear case) to ¥43.30 (bull case); at ¥32.43, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 7%, 603658 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥48.29) versus Asset-Based (¥10.47). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally.
Full company description
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an automatic immunoassay analyzer; AutoLumo A2000 Plus, an automated chemiluminescence immunoassay analyzer; PHOmo microplate readers; LUmo microplate luminometers; and iWO and iWO-960 microplate washers. The company's microbiology products include AutoMic-I60 for microbial identification and antibiotic susceptibility testing; AutoStreak S1800, a microbial sample pretreatment system; Autof T series and MALDI-TOF MS system for the identification of pathogenic bacteria; AutoMimo 1200, an instrument for improving pipetting efficiency and optimize workflow in the lab; BC60, an automatic blood culture instrument; and BC120, an automated bacterial culturing and detection. It also provides blood culture bottles and mycoplasma TIES reagents; AutoMolec 1600, an integrated and automated molecular diagnostics analyzer; AutoMolec 3000, an in vitro molecular detection instrument; Ci-120x and Ci-310 benchtop coagulation analyzers; and Autolas Bi 1000, Autolas Bi2600, AutoChem B861, and AutoChem B2000 automated biochemistry analyzers. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is headquartered in Zhengzhou, China. Autobio Diagnostics Co., Ltd. operates as a subsidiary of Zhengzhou Autobio Co., Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Autobio Diagnostics Co reported revenue of ¥4.2B in FY2025 versus ¥3.8B in FY2021, a compound +2.9%/yr. Reported net income was ¥1.1B in FY2025, compounding +2.3%/yr from FY2021.
Watch 603658: get an alert when its fair value changes →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Autobio Diagnostics Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Autobio Diagnostics Co (603658) overvalued or undervalued?
What is the fair value of 603658?
What is the quality score of 603658?
What is the revenue of Autobio Diagnostics Co (603658)?
What is the net profit margin of 603658?
Does Autobio Diagnostics Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Autobio Diagnostics Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.